ELIQUIS
PeakNDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
Priority Review
ELIQUIS by Bristol Myers Squibb is fxa. Approved for deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), knee replacement surgery and 7 more indications. First approved in 2012.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIQUIS (apixaban) is an oral Factor Xa inhibitor approved in 2012 that prevents blood clots by blocking free and clot-bound Factor Xa without requiring antithrombin III. It treats deep vein thrombosis (DVT), pulmonary embolism (PE), venous thromboembolism (VTE), and reduces stroke risk in nonvalvular atrial fibrillation patients. The drug works by decreasing thrombin generation and thrombus development through selective FXa inhibition.
$18.3BPart D
Peak5.2 years to LOEPeak lifecycle stage with $18.3B in annual spending indicates a large, mature brand team with strong resource allocation and career advancement opportunities.
Mechanism of Action
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…
Worked on ELIQUIS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.